Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19089650 | ELECTROPORATION-TARGETED DELIVERY OF RIBOSOME INACTIVATING PROTEIN GELONIN INTO MAMMALIAN CELLS | March 2025 | October 2025 | Allow | 6 | 1 | 0 | No | No |
| 18820753 | BACTERIOTHERAPY FOR CLOSTRIDIUM DIFFICILE COLITIS | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18639518 | BIOCOMPATIBLE CONDITIONED CELL MEDIUM COMPOSITIONS AND USES THEREOF | April 2024 | February 2026 | Allow | 22 | 2 | 0 | No | No |
| 18631959 | BACTERIOTHERAPY FOR CLOSTRIDIUM DIFFICILE COLITIS | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18626855 | SYSTEMS AND METHODS FOR GROWTH OF INTESTINAL CELLS IN MICROFLUIDIC DEVICES | April 2024 | March 2025 | Allow | 11 | 0 | 0 | No | No |
| 18581700 | ISLET CELL MANUFACTURING COMPOSITIONS AND METHODS OF USE | February 2024 | January 2025 | Allow | 11 | 0 | 0 | Yes | No |
| 18581245 | USE OF HSP70 AS A REGULATOR OF ENZYMATIC ACTIVITY | February 2024 | November 2025 | Allow | 21 | 1 | 1 | No | No |
| 18389801 | METHOD FOR THE PRODUCTION OF THYMOCYTE SUPERNATANT | December 2023 | September 2025 | Allow | 21 | 1 | 0 | No | No |
| 18544083 | BACTERIOTHERAPY FOR CLOSTRIDIUM DIFFICILE COLITIS | December 2023 | April 2024 | Allow | 4 | 1 | 0 | No | No |
| 18535652 | GLYCAN THERAPEUTIC COMPOSITIONS AND RELATED METHODS THEREOF | December 2023 | June 2025 | Allow | 18 | 1 | 0 | No | No |
| 18515559 | Pharmaceutical Composition of a Recombinant Adeno-Associated Virus Vector and its Application | November 2023 | May 2025 | Allow | 18 | 3 | 2 | No | No |
| 18497412 | BIFIDOBACTERIA FOR TREATING CARDIAC CONDITIONS | October 2023 | August 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18378133 | TWO-STAGE PROCESS FOR PRODUCING OIL FROM MICROALGAE | October 2023 | June 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18476483 | METHODS AND COMPOSITIONS FOR PRESERVING BACTERIA | September 2023 | July 2025 | Allow | 21 | 2 | 0 | Yes | No |
| 18454562 | COMPOSITION FOR PROMOTING THE GROWTH OF LACTIC ACID BACTERIA COMPRISING GROWTH FACTORS | August 2023 | October 2024 | Allow | 14 | 1 | 0 | No | No |
| 18230923 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DISEASES | August 2023 | May 2025 | Allow | 21 | 1 | 0 | No | No |
| 18343514 | BONE MARROW MICROFLUIDIC DEVICES AND METHODS FOR PREPARING AND USING THE SAME | June 2023 | August 2024 | Allow | 14 | 1 | 0 | No | No |
| 18338437 | Quality Assurance of Chondrocytes | June 2023 | November 2024 | Allow | 17 | 1 | 0 | No | No |
| 18337292 | STEM CELL CULTURE SYSTEMS FOR COLUMNAR EPITHELIAL STEM CELLS, AND USES RELATED THERETO | June 2023 | March 2025 | Allow | 21 | 1 | 1 | No | No |
| 18334098 | ACTIVATION OF IMMUNE CELLS | June 2023 | September 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18039848 | METHOD OF ENCAPSULATING SINGLE CELLS UTILIZING AN ALTERNATING CURRENT ELECTROSPRAY | June 2023 | September 2025 | Allow | 27 | 0 | 0 | No | No |
| 18202419 | STABILIZATION OF THROMBOCYTES AT AMBIENT TEMPERATURES | May 2023 | June 2024 | Allow | 13 | 1 | 0 | No | No |
| 18300427 | Scheduled Feed | April 2023 | April 2024 | Allow | 12 | 1 | 0 | Yes | No |
| 18127958 | METHODS AND MATERIALS FOR USING FIBRIN SUPPORTS FOR RETINAL PIGMENT EPITHELIUM TRANSPLANTATION | March 2023 | August 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18043405 | HYDROGELS FOR CELL CULTURE | February 2023 | February 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18175417 | QUANTIFYING CELL-DERIVED CHANGES IN COLLAGEN SYNTHESIS, ALIGNMENT, AND MECHANICS IN A 3D CONNECTIVE TISSUE MODEL | February 2023 | June 2025 | Allow | 28 | 1 | 0 | Yes | No |
| 18175433 | METHODS AND COMPOSITIONS FOR INCREASING SUSCEPTIBILITY TO RADIATION TREATMENT BY INHIBITING SUPPRESSION OF NUMERICAL CHROMOSOMAL INSTABILITY OF CANCER CELLS | February 2023 | June 2024 | Allow | 16 | 1 | 0 | No | No |
| 18167728 | DISORDERS IMPLICATING PUFA OXIDATION | February 2023 | July 2024 | Allow | 17 | 1 | 0 | No | No |
| 18101727 | METHODS OF MANUFACTURE OF THERAPEUTIC PRODUCTS COMPRISING VITALIZED PLACENTAL DISPERSIONS | January 2023 | January 2025 | Allow | 24 | 1 | 0 | No | No |
| 18100671 | Ex vivo tumour immune microenvironment model, a method for preserving a tumour-specific immune cell profile in an ex vivo tumour immune microenvironment model and use of nanofibrillar cellulose | January 2023 | March 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18155311 | METHOD FOR THE RAPID DETECTION OF BACTERIAL SPORES IN AN INDUSTRIAL PROCESS | January 2023 | August 2025 | Allow | 31 | 3 | 0 | No | No |
| 18097414 | DENTAL DEVICE FOR TOOTH WHITENING | January 2023 | March 2025 | Allow | 26 | 3 | 0 | No | No |
| 18015972 | METHODS FOR EVALUATING CARDIAC SAFETY OF DRUG USING CARDIOMYOCYTES DERIVED FROM HUMAN STEM CELLS | January 2023 | November 2025 | Allow | 34 | 1 | 0 | No | No |
| 18153320 | NASAL FOAM VIA CRIBRIFORM PLATE FOR MEDICATION DELIVERY TO THE BRAIN AND/OR BODY AND FOR NASAL MOISTURIZATION AND HYGIENE | January 2023 | December 2024 | Abandon | 23 | 2 | 0 | No | No |
| 18094883 | COMPOSITION WITH A TIME RELEASE MATERIAL FOR REMOVING HALOGENATED HYDROCARBONS FROM CONTAMINATED ENVIRONMENTS | January 2023 | February 2024 | Allow | 13 | 1 | 0 | No | No |
| 18147948 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF PROBIOTIC AND PREBIOTIC TO TREAT STUNTING | December 2022 | November 2025 | Abandon | 34 | 2 | 0 | No | Yes |
| 18147939 | CELL CULTURE SUBSTRATE, CANCER CELL AGGREGATE AND METHOD FOR MANUFACTURING SAME USING SAID SUBSTRATE, AND DRUG SCREENING METHOD USING SAID CANCER CELL AGGREGATE | December 2022 | February 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18146108 | METHOD OF SCREENING FOR A SUBSTANCE THAT ACTS ON A CELL MASS | December 2022 | September 2023 | Allow | 8 | 0 | 0 | No | No |
| 18065480 | METHODS, CULTURE MEDIAS AND DEVICES FOR GENERATING EMBRYOS IN VITRO FROM STEM CELLS | December 2022 | December 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17926102 | Preparation and Purification of Hypersialylated IGG | November 2022 | February 2026 | Allow | 39 | 1 | 1 | No | No |
| 17925943 | DETERMINING DRUG EFFECTS USING COMBINATION OF MEASUREMENTS | November 2022 | December 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17925998 | STABLY-INVERTED ORGANOIDS AND METHODS OF PRODUCING AND USING THE SAME | November 2022 | November 2025 | Allow | 36 | 1 | 0 | No | No |
| 17924646 | A HEPATITIS C NUCLEIC ACID VACCINE COMPRISING A VARIABLE DOMAIN DELETED E2 POLYPEPTIDE | November 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17921888 | CONFORMAL COATING OF CELLS FOR IMMUNOISOLATION | October 2022 | November 2025 | Allow | 36 | 1 | 0 | No | No |
| 17973909 | HUMAN ORIGIN PROBIOTIC LACTOBACILIUS RHAMNOSUS HL-200 TO REDUCE LEAKY GUT BY METABOLIZING ETHANOLAMINE | October 2022 | June 2025 | Allow | 31 | 4 | 1 | No | No |
| 17971686 | METHODS AND SYSTEMS FOR IN-VITRO MILK PRODUCTION | October 2022 | May 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17996611 | ADENO-ASSOCIATED VIRUS WITH ENGINEERED CAPSID | October 2022 | June 2025 | Allow | 32 | 0 | 0 | No | No |
| 17961276 | METHOD FOR TARGETED REGULATION OF SOIL MICROBES TO SYNCHRONIZE HEAVY METAL/METALLOID TRANSFORMATION AND GREENHOUSE GAS EMISSION REDUCTION AND USE | October 2022 | August 2023 | Allow | 10 | 1 | 0 | No | No |
| 17995543 | PCR BASED DIAGNOSTIC KIT, COMPOSITIONS AND METHODS FOR AMPLIFICATION AND DETECTION OF SARS-COV-2 | October 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17916369 | CORONAVIRUS VACCINES | September 2022 | November 2025 | Allow | 38 | 1 | 0 | No | No |
| 17914319 | METHODS, OLIGONUCLEOTIDES, AND KITS FOR DETECTION AND TREATMENT OF CORONAVIRUS | September 2022 | January 2026 | Allow | 40 | 1 | 1 | No | No |
| 17934460 | STIMULATION OF MESENCHYMAL STEM CELL THERAPEUTIC ACTIVITIES BY T REGULATORY CELLS | September 2022 | May 2024 | Allow | 19 | 1 | 0 | No | No |
| 17950446 | Nerve Guidance Conduit Comprising Neural Crest Stem-Like Cells and/or Schwann Cell Precursor-Like Cells and Methods of Making and Using the Same | September 2022 | January 2026 | Allow | 40 | 1 | 1 | No | No |
| 17906645 | HEART TISSUE MODEL | September 2022 | February 2026 | Allow | 41 | 1 | 1 | Yes | No |
| 17905873 | RAPID SCREEN FOR ANTIBIOTIC RESISTANCE AND TREATMENT REGIMEN | September 2022 | January 2026 | Allow | 40 | 2 | 0 | No | No |
| 17822860 | METHODS AND COMPOSITIONS FOR PRESERVING BACTERIA | August 2022 | June 2023 | Allow | 10 | 0 | 0 | No | No |
| 17886274 | BACTERIOTHERAPY FOR CLOSTRIDIUM DIFFICILE COLITIS | August 2022 | January 2024 | Allow | 17 | 1 | 0 | No | No |
| 17798824 | METHOD AND DRUG FOR TREATING VIRAL PNEUMONIA | August 2022 | February 2026 | Abandon | 42 | 1 | 1 | No | No |
| 17861912 | METHODS FOR TREATING INFLAMMATORY CONDITIONS OF THE LUNGS | July 2022 | October 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17861764 | PROCESS FOR PRODUCING PLATELET-RICH FIBRIN MATRIX FROM PLATELET-RICH PLASMA | July 2022 | July 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17856121 | NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS | July 2022 | March 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17788514 | COMPOSITION CONTAINING SESAMIN AND PQQ | June 2022 | July 2025 | Allow | 36 | 1 | 0 | No | No |
| 17842610 | METHODS AND COMPOSITIONS TO PROMOTING RETINAL REGENERATION USING PROX1 MIGRATION INHIBITOR AS ACTIVE INGREDIENT | June 2022 | January 2026 | Allow | 43 | 2 | 0 | No | No |
| 17786256 | LON PROTEASE, ALPHA-HEMOLYSIN, CK1-ALPHA-1; C-MYB INHIBITOR OR A CEBP-DELTA INHIBITOR AS THERAPEUTICS | June 2022 | November 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17778328 | ARCHAEAL PEPTIDE RECOMBINASE - A NOVEL PEPTIDE LIGATING ENZYME | May 2022 | December 2025 | Allow | 43 | 3 | 1 | Yes | No |
| 17747322 | ANTIBODY CONJUGATED NANOPARTICLE ASSAY AND TREATMENT FOR SARS-CoV-2 | May 2022 | May 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17727323 | BIOCOMPATIBLE CONDITIONED CELL MEDIUM COMPOSITIONS AND USES THEREOF | April 2022 | January 2024 | Allow | 21 | 1 | 0 | No | No |
| 17770451 | METHODS AND SYSTEMS FOR PERFORMING PERFUSION CELL CULTURE | April 2022 | July 2025 | Allow | 39 | 1 | 1 | No | No |
| 17721604 | CROSSLINKED SOFT TISSUE GRAFT AND METHODS OF USE THEREOF | April 2022 | March 2024 | Allow | 23 | 1 | 0 | No | No |
| 17659021 | Soluble Intein Fusion Proteins And Methods For Purifying Biomolecules | April 2022 | January 2024 | Allow | 22 | 2 | 0 | No | No |
| 17763171 | METHOD FOR CULTURING HAEMATOCOCCUS PLUVIALIS TO PRODUCE ASTAXANTHIN | March 2022 | December 2024 | Allow | 33 | 2 | 1 | No | No |
| 17688189 | USE OF HSP70 AS A REGULATOR OF ENZYMATIC ACTIVITY | March 2022 | December 2023 | Allow | 21 | 1 | 0 | No | No |
| 17678634 | MICROBIAL COMPOSITIONS AND METHODS OF USE FOR IMPROVING MILK PRODUCTION | February 2022 | October 2023 | Allow | 20 | 1 | 0 | No | No |
| 17678485 | SYSTEMS AND METHODS FOR GROWTH OF INTESTINAL CELLS IN MICROFLUIDIC DEVICES | February 2022 | November 2023 | Allow | 21 | 2 | 0 | No | No |
| 17677727 | TUMORICIDAL AND ANTIMICROBIAL COMPOSITIONS AND METHODS | February 2022 | April 2024 | Allow | 26 | 2 | 1 | No | No |
| 17672443 | ASSAYS FOR IMPROVING AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING ACCURACY | February 2022 | July 2023 | Allow | 17 | 1 | 0 | No | No |
| 17634876 | YEAST HAVING IMPROVEMENT OF LACTIC ACID TOLERANCE AND USE THEREOF | February 2022 | February 2024 | Allow | 24 | 2 | 0 | No | No |
| 17666034 | BIFIDOBACTERIA FOR TREATING CARDIAC CONDITIONS | February 2022 | November 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17310418 | THREE-DIMENSIONAL CULTURE METHOD FOR LARGE-SCALE PREPARATION OF STEM CELLS | February 2022 | April 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17589667 | 21-Hydroxylation of Steroids | January 2022 | December 2023 | Allow | 23 | 2 | 0 | No | No |
| 17576349 | Methods for Preparing Data from Tissue Sections for Machine Learning Using Both Brightfield and Fluorescent Imaging | January 2022 | September 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17645423 | NOVEL CAMPYLOBACTER BACTERIOPHAGES AND USES THEREOF | December 2021 | May 2025 | Allow | 41 | 3 | 1 | Yes | No |
| 17556650 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING VIRAL INFECTIONS | December 2021 | June 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17619722 | METHOD FOR STABILIZING INTRACELLULAR RNA | December 2021 | September 2025 | Allow | 45 | 1 | 1 | No | No |
| 17542551 | METHODS AND SYSTEMS FOR IN-VITRO MILK PRODUCTION | December 2021 | June 2022 | Allow | 6 | 2 | 0 | No | No |
| 17542568 | METHODS AND SYSTEMS FOR IN-VITRO MILK PRODUCTION | December 2021 | April 2022 | Allow | 4 | 1 | 0 | No | No |
| 17542552 | METHODS AND SYSTEMS FOR IN-VITRO MILK PRODUCTION | December 2021 | March 2022 | Allow | 4 | 1 | 0 | No | No |
| 17542599 | METHODS AND SYSTEMS FOR IN-VITRO MILK PRODUCTION | December 2021 | May 2022 | Allow | 6 | 1 | 0 | No | No |
| 17542570 | METHODS AND SYSTEMS FOR IN-VITRO MILK PRODUCTION | December 2021 | May 2022 | Allow | 6 | 1 | 0 | No | No |
| 17539155 | TUMORICIDAL AND ANTIMICROBIAL COMPOSITIONS AND METHODS | November 2021 | January 2024 | Allow | 26 | 1 | 0 | No | No |
| 17534977 | ISOLATED HUMAN LUNG PROGENITOR CELLS AND USES THEREOF | November 2021 | January 2024 | Allow | 26 | 2 | 0 | No | No |
| 17610129 | METHOD FOR EXTRACTING USEFUL SUBSTANCES FROM SHRIMP SHELLS | November 2021 | January 2025 | Allow | 38 | 1 | 0 | No | No |
| 17594570 | Genetically Encoded Tyrosine Sulfation of Proteins in Eukaryotes | October 2021 | July 2025 | Allow | 45 | 2 | 1 | No | No |
| 17602271 | LABEL-FREE DETECTION OF MYCOBACTERIA USING SURFACE ENHANCED RAMAN SPECTROSCOPY | October 2021 | March 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17495411 | XENO-FREE GENERATION OF TISSUE-SPECIFIC PROGENITOR CELLS | October 2021 | September 2024 | Allow | 35 | 2 | 0 | Yes | Yes |
| 17472737 | METHOD FOR PURIFYING AND QUANTIFYING THROMBIN AND ITS DEGRADATION POLYPEPTIDES | September 2021 | March 2025 | Allow | 42 | 2 | 0 | No | No |
| 17436148 | ANTIBACTERIAL COMPOSITION AGAINST DRUG-RESISTANT BACTERIA OR PRO-INFLAMMATORY BACTERIA | September 2021 | May 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17461347 | VEHICLES FOR APPLYING BACTERIA TO SKIN, SCALP, AND HAIR | August 2021 | April 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17434885 | BIOLOGICAL WATER-QUALITY DETECTION METHOD USING OBSTRUCTIVE MULTI-MODULE BIOLOGICAL WATER-QUALITY DETECTION DEVICE | August 2021 | October 2024 | Allow | 37 | 1 | 0 | No | No |
| 17445975 | FEED AND FOOD | August 2021 | November 2024 | Allow | 38 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BERKE-SCHLESSEL, DAVID W.
With a 52.9% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 19.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BERKE-SCHLESSEL, DAVID W works in Art Unit 1651 and has examined 696 patent applications in our dataset. With an allowance rate of 65.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 31 months.
Examiner BERKE-SCHLESSEL, DAVID W's allowance rate of 65.2% places them in the 26% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by BERKE-SCHLESSEL, DAVID W receive 1.99 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by BERKE-SCHLESSEL, DAVID W is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +37.0% benefit to allowance rate for applications examined by BERKE-SCHLESSEL, DAVID W. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 30.2% of applications are subsequently allowed. This success rate is in the 59% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 35.3% of cases where such amendments are filed. This entry rate is in the 53% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 87.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 66% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 58.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 70.5% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 55% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.